Quantcast

Latest Avandia Stories

2010-09-23 10:25:00

Makes regulatory decisions on RECORD and TIDE trials SILVER SPRING, Md., Sept. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients...

2010-08-24 15:00:00

Study highlights: A new analysis of data on patients covered by a single insurance company reports that risks of heart disease events and death were no different between patients who took the diabetes drugs rosiglitazone or pioglitazone. In this analysis, approximately 4 percent of patients taking either drug - sold as Avandia and Actos - suffered a heart attack, heart failure, both or died over a 33-month period. See links below to the American Heart Association's statement on TZDs and...

2010-07-22 12:32:13

Discovery raises possibility of safer, more selective diabetes drugs A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute. "Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered...

815831c2f7b1a24cd3c41f381562448f1
2010-07-22 07:50:00

Federal health authorities are prohibiting new patients from enrolling in a safety study for GlaxoSmithKline's controversial diabetes pill Avandia, a week after an expert panel ruled that the drug increases heart risks. The Associated Press (AP) reported Wednesday that the Food and Drug Administration (FDA) said it issued a "partial clinical hold" on the study to update researchers on the latest concerns about the drug, which has been under a close eye since 2007. Although the panel of...

b0957c64f088eedca4cb437867702267
2010-07-15 06:05:00

A panel of U.S. Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill. The panel of experts voted 20-12 to retain availability of Avandia to diabetics, although 10 panelists called for limiting who can receive and prescribe the once-blockbuster medication. British drugmaker Glaxo has been hit with thousands of lawsuits from...

2010-07-14 16:53:00

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions (20) to withdrawal from the U.S. market (12). "Following today's recommendations, we will, of course, continue...

86cee565efd865d6a24c9732f5d7e7b8
2010-07-13 13:37:42

GlaxoSmithKline Plc stood up for its diabetes pill Avandia against U.S. advisers this week, claiming that it was safe and should stay on the market. The scientific experts assembled by the U.S. Food and Drug Administration are sorting through cases to determine whether Avandia causes heart attacks. "Follow the science where it leads and the rest will fall into place," FDA Commissioner Margaret Hamburg said in the opening of a meeting held in a packed hotel ballroom, acknowledging that the...

2010-02-24 09:24:00

RESEARCH TRIANGLE PARK, N.C., Feb. 24 /PRNewswire-FirstCall/ -- Today, GlaxoSmithKline (NYSE: GSK) responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report"). To view GSK's response, visit http://www.gsk.com/media/GSK-White-Paper-Avandia-23-Feb-2010.pdf. In its response, GSK states that the Staff Report fails to present an accurate, balanced, or complete view of the currently available...

2009-11-03 10:40:00

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes http://www.reportlinker.com/p0157514/Commercial-Insight-Antidiabetics-in-Australia---Reimbursement-status-shapes-novel-classes.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Introduction The author expects the Australian antidiabetics market to...

3df61040d68dde9297d77f28431299631
2009-06-08 10:30:00

U.S. researchers said on Sunday that diabetics with stable heart disease do just as well taking drugs alone as getting quick angioplasty or bypass surgery to open blocked heart arteries, Reuters reported.The report said heart patients could safely wait and give drugs a chance to work, rather than immediately undergoing angioplasty and a heart stent to restore blood flow and ease chest pain.However, it acknowledged that patients with more severe disease sent for more invasive heart bypass...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related